• Passage Bio to Participate in Upcoming March Investor Conferences

    Источник: Nasdaq GlobeNewswire / 01 мар 2022 07:00:03   America/New_York

    PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in two upcoming virtual investor conferences in March:

    Cowen 42nd Annual Healthcare Conference
    Format: Panel
    Date: Tuesday, March 8, 2022
    Time: 2:10 p.m. ET

    Oppenheimer 32nd Annual Healthcare Conference
    Format: Presentation
    Date: Tuesday, March 15, 2022
    Time: 4:40 p.m. ET

    A live webcast of the events will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentations will be available for 30 days following the events.

    About Passage Bio

    At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

    For further information, please contact:

    Investors:
    Stuart Henderson
    Passage Bio
    267.866.0114
    shenderson@passagebio.com

    Media:
    Gwen Fisher
    Passage Bio
    215.407.1548
    gfisher@passagebio.com


    Primary Logo

Опубликовать